Transfer genetically modified cells into humans
|
|
|
|
|
|
|
Life-long persistence of genetically modified cells in recipient
|
|
|
|
|
|
|
Side-effects e.g. cytokine release syndrome, neurotoxicity, Graft versus Host Disease (GvHD)
|
|
|
|
|
|
|
Socio-economic burden for health care systems through high costs of ATMP/CAR T cell products
|
|
|
|
|
|
|
Lack of appropriate reimbursement models
|
|
|
|
|
|
|
Limited access of patients to novel Advanced Therapies
|
|
|
|
|
|
|
Dependency on pharma/biotech industry
|
|
|
|
|
|
|
Unrealistic public expectations on therapeutic potential of Advanced Therapies
|
|
|
|
|
|
|